Robert C. Scott
Impact in
- Surgery top 0.1%
- Lipoproteins and Cardiovascular Health
- Cholesterol and Lipid Metabolism
- Coronary Interventions and Diagnostics
- Pharmaceutical Science top 0.5%
- Drug Solubulity and Delivery Systems
- Advancements in Transdermal Drug Delivery
Papers in
- Surgery 59
- Lipoproteins and Cardiovascular Health 52
-
- Aeroelasticity and Vibration Control 14
- Aerospace and Aviation Technology 5
- Co-authors
- Scott M. Wasserman (43 shared papers)Evan A. Stein (10 shared papers)Ransi M. Somaratne (22 shared papers)Frederick Johan Raal (13 shared papers)Sarah Gould (1 shared paper)Michael J. Koren (11 shared papers)Dirk Jacobus Blom (9 shared papers)Philip A. Horvath (3 shared papers)
- Journals
- Journal of the American College of Cardiology (10 papers)The Lancet (6 papers)Circulation (5 papers)JAMA (4 papers)European Heart Journal (3 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Robert C. Scott
128 papers receiving 11.9k citations
Robert C. Scott's Hit Papers
Peers
Comparison fields: 5 of 166
- Surgery 8.4k
- Pharmaceutical Science 692
- Cardiology and Cardiovascular Medicine 635
- Finance 288
- Immunology 465
Countries citing papers authored by Robert C. Scott
This map shows the geographic impact of Robert C. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Scott more than expected).
Fields of papers citing papers by Robert C. Scott
This network shows the impact of papers produced by Robert C. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Scott. The network helps show where Robert C. Scott may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert C. Scott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 132 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events Hit paper breakdown → | 2015 | 1254 |
| 2 | Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients Hit paper breakdown → | 2016 | 935 |
| 3 | 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review Hit paper breakdown → | 2005 | 659 |
| 4 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 644 |
| 5 | A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia Hit paper breakdown → | 2014 | 620 |
| 6 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 618 |
| 7 | Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance Hit paper breakdown → | 2014 | 460 |
| 8 | Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia Hit paper breakdown → | 2014 | 446 |
| 9 | Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia Hit paper breakdown → | 2012 | 431 |
| 10 | 1980 | 429 | |
| 11 | Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients Hit paper breakdown → | 2012 | 397 |
| 12 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Hit paper breakdown → | 2012 | 377 |
| 13 | Anti-PCSK9 Monotherapy for Hypercholesterolemia Hit paper breakdown → | 2014 | 361 |
| 14 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Hit paper breakdown → | 2012 | 314 |
| 15 | Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) Hit paper breakdown → | 2014 | 306 |
| 16 | Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia Hit paper breakdown → | 2013 | 291 |
| 17 | 2013 | 188 | |
| 18 | 1988 | 185 | |
| 19 | 2016 | 182 | |
| 20 | 2008 | 169 |
About Robert C. Scott
Robert C. Scott is a scholar working on Surgery, Aerospace Engineering, Economics and Econometrics, Pharmaceutical Science and Pharmacology, having authored 132 papers that have together received 12.5k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (52 papers), Aeroelasticity and Vibration Control (14 papers), Pesticide Exposure and Toxicity (7 papers), Aerospace and Aviation Technology (5 papers), Nanoparticle-Based Drug Delivery (5 papers), Innovation Policy and R&D (5 papers), Advancements in Transdermal Drug Delivery (4 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). The work is most often cited by research in Surgery (8.4k citations), Pharmaceutical Science (692 citations), Cardiology and Cardiovascular Medicine (635 citations), Finance (288 citations) and Immunology (465 citations). Robert C. Scott has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Scott M. Wasserman, Evan A. Stein, Ransi M. Somaratne, Frederick Johan Raal, Sarah Gould, Michael J. Koren, Dirk Jacobus Blom, Philip A. Horvath, Marc Steven Sabatine and Robert Patrick Giugliano. Their work appears in journals such as Journal of the American College of Cardiology, The Lancet, Circulation, JAMA and European Heart Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.